To analyze the effects of MEK inhibition on the immunogenicity of lung cancer cells, we analyzed the expression of both major histocompatibility complex class-I (MHC-I) by western blot and of several cytokines by RT-qPCR after treatment with selumetinib. Here, MAP2K7 is linked to lung cancer.